MedPal AI (MPAL) has reported strong early operational performance from its pharmacy division, with almost 147,000 prescription items dispensed in the first four months since launching operations in November 2025.
The AI-powered digital health company said its wholly owned subsidiary, MedPal Limited, generated turnover of more than £1.5 million during the period, with an average gross margin of about 33%.
MedPal dispensed 32,637 prescription items in February 2026 alone, maintaining a high level of activity and supporting monthly pharmacy revenue of more than £300,000.
The company combines an AI-driven diagnosis and triage system with human clinical oversight and prescribing services through its mobile platform. This is integrated with a high-tech robotic dispensing operation based at the company’s national distribution centre.
Furthermore, the company said the sustained growth in dispensing volumes reflects increasing patient demand for both National Health Service (NHS) and private prescriptions, including through the MedPal.clinic weight-loss platform.
MedPal AI’s CEO Jason Drummond said: “Dispensing nearly 147,000 prescription items and generating turnover in excess of £1.5 million in our first four months of pharmacy operations is an outstanding achievement for the Company. This performance validates the scalability and commercial viability of our automated dispensing model and the strength of our vertically integrated platform.
“We continue to see strong demand across both our NHS Distance Selling Pharmacy contract and our private weight-loss services through MedPal.clinic, and we look forward to updating the market on continued progress.”
View from Vox
MedPal AI’s early dispensing figures provide a first indication of how its vertically integrated digital health platform is translating into revenue. Strong volumes, combined with a reported gross margin of about 33%, suggest the automated pharmacy model could scale efficiently as demand grows. Meanwhile, the mix of NHS prescriptions and private weight-loss treatments may provide multiple revenue streams as the platform expands.